Research output: Contribution to journal › Article › peer-review
Blood metabolite markers of neocortical amyloid-β burden : discovery and enrichment using candidate proteins. / Voyle, N; Kim, M; Proitsi, P et al.
In: Translational psychiatry, Vol. 6, e719, 02.2017.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Blood metabolite markers of neocortical amyloid-β burden
T2 - discovery and enrichment using candidate proteins
AU - Voyle, N
AU - Kim, M
AU - Proitsi, P
AU - Ashton, N J
AU - Baird, A L
AU - Bazenet, C
AU - Hye, A
AU - Westwood, S
AU - Chung, R
AU - Ward, M
AU - Rabinovici, G D
AU - Lovestone, S
AU - Breen, G
AU - Legido-Quigley, C
AU - Dobson, R J B
AU - Kiddle, S J
PY - 2017/2
Y1 - 2017/2
N2 - We believe this is the first study to investigate associations between blood metabolites and neocortical amyloid burden (NAB) in the search for a blood-based biomarker for Alzheimer's disease (AD). Further, we present the first multi-modal analysis of blood markers in this field. We used blood plasma samples from 91 subjects enrolled in the University of California, San Francisco Alzheimer's Disease Research Centre. Non-targeted metabolomic analysis was used to look for associations with NAB using both single and multiple metabolic feature models. Five metabolic features identified subjects with high NAB, with 72% accuracy. We were able to putatively identify four metabolites from this panel and improve the model further by adding fibrinogen gamma chain protein measures (accuracy=79%). One of the five metabolic features was studied in the Alzheimer's Disease Neuroimaging Initiative cohort, but results were inconclusive. If replicated in larger, independent studies, these metabolic features and proteins could form the basis of a blood test with potential for enrichment of amyloid pathology in anti-amyloid trials.
AB - We believe this is the first study to investigate associations between blood metabolites and neocortical amyloid burden (NAB) in the search for a blood-based biomarker for Alzheimer's disease (AD). Further, we present the first multi-modal analysis of blood markers in this field. We used blood plasma samples from 91 subjects enrolled in the University of California, San Francisco Alzheimer's Disease Research Centre. Non-targeted metabolomic analysis was used to look for associations with NAB using both single and multiple metabolic feature models. Five metabolic features identified subjects with high NAB, with 72% accuracy. We were able to putatively identify four metabolites from this panel and improve the model further by adding fibrinogen gamma chain protein measures (accuracy=79%). One of the five metabolic features was studied in the Alzheimer's Disease Neuroimaging Initiative cohort, but results were inconclusive. If replicated in larger, independent studies, these metabolic features and proteins could form the basis of a blood test with potential for enrichment of amyloid pathology in anti-amyloid trials.
UR - http://www.scopus.com/inward/record.url?scp=85016160687&partnerID=8YFLogxK
U2 - 10.1038/tp.2015.205
DO - 10.1038/tp.2015.205
M3 - Article
C2 - 26812040
VL - 6
JO - Translational psychiatry
JF - Translational psychiatry
SN - 2158-3188
M1 - e719
ER -
King's College London - Homepage
© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454